SupraRNA SIGNED
A Comprehensive Supramolecular Approach for an RNA vaccine for Influenza A (H1N1)
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SupraRNA project word cloud
Explore the words cloud of the SupraRNA project. It provides you a very rough idea of what is the project "SupraRNA" about.
Project "SupraRNA" data sheet
The following table provides information about the project.
| Coordinator |
THE UNIVERSITY OF BIRMINGHAM
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 212˙933 € |
| EC max contribution | 212˙933 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2019 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-05-01 to 2022-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THE UNIVERSITY OF BIRMINGHAM | UK (BIRMINGHAM) | coordinator | 212˙933.00 |
Map
Project objective
*The development of vaccines is key for disease prevention, and is a major focus globally in the healthcare sector. Seasonal influenza is an acute respiratory infection caused by influenza viruses which circulate in all parts of the world. Seasonally, it remains a persistent health threat and has been declared an epidemic in some states. Typical vaccines have been less effective against rapidly evolving pathogens such as influenza. A new class of vaccines based on nucleic acids, namely RNA, have recently been developed and show immense promise due to their robust nature, short manufacturing times and enhanced efficacy. Here we propose an RNA delivery system based on a supramolecular assembly approach for the vaccination of influenza A H1N1 strain. Specifically, a π-amphiphile will be used as the platform molecule for covalent RNA conjugation and delivery. A messenger RNA (mRNA) targeting the hemagglutinin (HA) gene from a model influenza virus strain will be employed as the therapeutic (H1N1/PR8-HA). The central π-amphiphile moiety will be functionalized with the mRNA strand via a redox responsive disulfide bond, and hydrophilic oligo-oxy aryl groups connected via a hydrogen bonding unit to promote self-assembly. Steric stabilization will be afforded to the surface decorated mRNA to protect from enzymatic hydrolysis in the complex biological environments, through co-assembly with an analogue π-amphiphile which has been alternatively decorated with poly(ethylene glycol) (PEG) chains. Efficient intracellular transport of the delivery vehicle to achieve optimum mRNA transfection will be achieved through the incorporation of a TAT-peptide on the PEG chain end. The therapeutic efficacy of the nanoassembly will be evaluated through transfection efficacy in macrophage cell lines. Overall, this proposal aims to lay the groundwork for extending the scope of RNA vaccines by exploring the potential of supramolecular assemblies as a delivery vector.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPRARNA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SUPRARNA" are provided by the European Opendata Portal: CORDIS opendata.